IMMUNEONCO-B (01541) saw its shares rise more than 10%. At the time of writing, the stock was up 10.46%, trading at HK$5.28, with a turnover of HK$7.03 million. On March 17, the company announced that its self-developed drug, Amurelifup α (IMM0306), has received official approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for the treatment of Primary Membranous Nephropathy (PMN). This marks another significant milestone for IMM0306 in the field of autoimmune kidney diseases, representing a substantial step forward for the innovative drug in nephrology treatment. The company stated that the Phase II clinical approval for IMM0306 in treating PMN, along with the recent development of its subcutaneous injection formulation (IMM0306S), highlights IMMUNEONCO-B's concentrated efforts in the autoimmune disease sector and reflects its strategic progress in achieving multiple breakthroughs across its autoimmune pipeline.